含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察(1)
摘 要：目的 探讨含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效。方法 选取我院2013年5月～2017年5月收治的120例骨肉瘤患者作为研究对象，采用随机数字表法分为观察组和对照组，各60例。观察组患者采用含洛铂的新辅助动脉灌注化疗联合保肢手术及术后辅助化疗治疗，对照组患者采用传统保肢手术联合术后化疗，分别从近期临床化疗临床效果、化疗不良反应(胃肠道反应、白细胞下降、末梢神经毒性、血小板减少、发热、肾功能损害、肝功能损害、骨髓抑制等)比较两组患者近期临床疗效;从肢体功能Enneking评分及优良率比较两组患者远期临床疗效。结果 观察组患者近期临床化疗总有效率95.00%，远高于对照组患者的75.00%(P<0.05);且观察组不良反应发生率仅为 16.67%，远低于对照组的35.00%(P<0.05);观察组患者Enneking评分为(26.11±2.37)分，高于对照组(24.52±3.69)分;且观察组优良率为83.33%，高于对照组的60.00%(P<0.05)。结论 含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤具有良好的近远期临床疗效。
, 百拇医药
关键词：洛铂;新辅助化疗;保肢手术;骨肉瘤
中图分类号：R738.1 文獻标识码：A DOI：10.3969/j.issn.1006-1959.2018.21.022
文章编号：1006-1959(2018)21-0083-04
Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for Osteosarcoma
SU Zhi1，WU Wei2，WU Zhi-gang1，QUAN Dong1，XIN Ren1，WANG Jian-gong1，NIE Lin-yang1
, 百拇医药
(1.Department of Orthopedics，PLA 518th Hospital， Xi 'an 710043 ，Shaanxi，China;
2. PLA 65547 Army Medical Company，Anshan 114200，Liaoning，China)
Abstract：Objective To explore the clinical efficacy of neoadjuvant chemotherapy with losplatin combined with limb salvage in the treatment of osteosarcoma.Methods From May 2013 to May 2017 treated 120 cases of patients with osteosarcoma as the research object， were randomly divided into observation group (n=60) and control group (n=60)，the patients in the observation group were treated with neoadjuvant arterial infusion chemotherapy containing loplatin combined with limb salvage surgery and postoperative adjuvant chemotherapy， while the patients in the control group were treated with traditional limb salvage surgery combined with postoperative chemotherapy. Side effects of chemotherapy (gastrointestinal reaction， leukopenia， peripheral neurotoxicity， thrombocytopenia， fever， renal function damage， liver function damage， bone marrow depression， etc.) were compared between the two groups. To compare the long-term clinical effect of the two groups from limb function Enneking score and excellent and good rate.Results The short-term clinical efficacy data showed that the total effective rate of clinical chemotherapy in the observation group was 95.00%， which was much higher than 75.00% of the control group (P<0.05).The incidence of adverse reactions in the observation group was only 16.67%， which was much lower than 35.00% in the control group (P<0.05). The Enneking score of the observation group was (26.11±2.37)， which was higher than that of the control group (24.52±3.69). The excellent and good rate of the observation group was 83.33%， which was higher than that of the control group 60.00% (P<0.05). Conclusion Neoadjuvant chemotherapy with lobaplatin combined with limb salvage surgery for osteosarcoma has a good near-term clinical effect.Conclusion Neoadjuvant chemotherapy with loroplatin-containing regimen combined with limb salvage surgery has good short-term and long-term clinical efficacy in the treatment of osteosarcoma., 百拇医药(苏 志 吴 蔚 吴智钢 权 冬 辛 忍 王建功 聂林洋)
, 百拇医药
关键词：洛铂;新辅助化疗;保肢手术;骨肉瘤
中图分类号：R738.1 文獻标识码：A DOI：10.3969/j.issn.1006-1959.2018.21.022
文章编号：1006-1959(2018)21-0083-04
Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for Osteosarcoma
SU Zhi1，WU Wei2，WU Zhi-gang1，QUAN Dong1，XIN Ren1，WANG Jian-gong1，NIE Lin-yang1
, 百拇医药
(1.Department of Orthopedics，PLA 518th Hospital， Xi 'an 710043 ，Shaanxi，China;
2. PLA 65547 Army Medical Company，Anshan 114200，Liaoning，China)
Abstract：Objective To explore the clinical efficacy of neoadjuvant chemotherapy with losplatin combined with limb salvage in the treatment of osteosarcoma.Methods From May 2013 to May 2017 treated 120 cases of patients with osteosarcoma as the research object， were randomly divided into observation group (n=60) and control group (n=60)，the patients in the observation group were treated with neoadjuvant arterial infusion chemotherapy containing loplatin combined with limb salvage surgery and postoperative adjuvant chemotherapy， while the patients in the control group were treated with traditional limb salvage surgery combined with postoperative chemotherapy. Side effects of chemotherapy (gastrointestinal reaction， leukopenia， peripheral neurotoxicity， thrombocytopenia， fever， renal function damage， liver function damage， bone marrow depression， etc.) were compared between the two groups. To compare the long-term clinical effect of the two groups from limb function Enneking score and excellent and good rate.Results The short-term clinical efficacy data showed that the total effective rate of clinical chemotherapy in the observation group was 95.00%， which was much higher than 75.00% of the control group (P<0.05).The incidence of adverse reactions in the observation group was only 16.67%， which was much lower than 35.00% in the control group (P<0.05). The Enneking score of the observation group was (26.11±2.37)， which was higher than that of the control group (24.52±3.69). The excellent and good rate of the observation group was 83.33%， which was higher than that of the control group 60.00% (P<0.05). Conclusion Neoadjuvant chemotherapy with lobaplatin combined with limb salvage surgery for osteosarcoma has a good near-term clinical effect.Conclusion Neoadjuvant chemotherapy with loroplatin-containing regimen combined with limb salvage surgery has good short-term and long-term clinical efficacy in the treatment of osteosarcoma., 百拇医药(苏 志 吴 蔚 吴智钢 权 冬 辛 忍 王建功 聂林洋)